Millenium Pharmaceuticals, in collaboration with the Whitehead Institute, USA and Lund University in Sweden, among others, has reported on the mapping of a gene that may be associated with the development of a form of adult-onset diabetes which is linked to the low secretion of insulin. This was reported in the September issue of Nature Genetics.
The identification of the chromosomal location of the gene, referred to as NIDDM2, is thought to be an important advance towards the understanding of the etiology of human diabetes, say the researchers, and may contribute to the development of new therapeutic interventions for the disease.
Over 4,000 individuals from the Botnia region in western Finland, took part in a scanning project. To be included in the study, subjects must have had a minimum of three affected family members, with one having developed the disease before the age of 60, and one before the age of 65. The study ultimately involved 26 families and 217 individuals of whom120 were diabetic patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze